Oxidative Aromatization of 4,7-Dihydro-6-nitroazolo[1,5-a]pyrimidines: Synthetic Possibilities and Limitations, Mechanism of Destruction, and the Theoretical and Experimental Substantiation

Daniil N. Lyapustin 1, Evgeny N. Ulomsky 1,2, Ilya A. Balyakin 3,4, Alexander V. Shchepochkin 2, Vladimir L. Rusinov 1,2,* and Oleg N. Chupakhin 1,2

1 Department of Organic and Biomolecular Chemistry, Ural Federal University, Mira St. 19, 620002 Ekaterinburg, Russia; lyapustin.danil@yandex.ru (D.N.L.); ulomsky@yandex.ru (E.N.U.); chupakhin@ios.uran.ru (O.N.C.)
2 Institute of Organic Synthesis, Ural Branch of the Russian Academy of Sciences, S. Kovalevskaya Str., 22, 620041 Ekaterinburg, Russia; sasha-mmm@mail.ru
3 NANOTECH Centre, Ural Federal University, 620002 Ekaterinburg, Russia; i.a.balyakin@gmail.com
4 Institute of Metallurgy, Ural Branch of the Russian Academy of Sciences, 620016 Ekaterinburg, Russia
* Correspondence: v.l.rusinov@urfu.ru

Abstract: The reaction tolerance of the multicomponent process between 3-aminoazoles, 1-morpholin-2-nitroalkenes, and aldehydes was studied. The main patterns of this reaction have been established. Conditions for the oxidation of 4,7-dihydro-6-nitroazolo[1,5-a]pyrimidines were selected. Previous claims that the 4,7-dihydro-6-nitroazolo[1,5-a]pyrimidines could not be aromatised have now been refuted. Compounds with an electron-donor substituent at position seven undergo decomposition during oxidation. The phenomenon was explained based on experimental data, electro-chemical experiment, and quantum-chemical calculation. The mechanism of oxidative degradation has been proposed.

Keywords: azolo[1,5-a]pyrimidines; nitro-synthons; oxidation; oxidative destruction; synthesis of heterocycles; multicomponent reactions; nitro compounds

1. Introduction

Azolo[1,5-a]pyrimidines are a very diversified group of heterocycles [1–3]. Among them, many compounds find application due to their beneficial features, for example, photophysical properties [4–7], metal complexes [8–10], and as medicinal drugs for diabetes mellitus [11–13], viruses [14–16], bacteria [17,18], neurological diseases [19,20], tumor diseases [21–26], Alzheimer’s disease [27–29], etc.

A special place is occupied by 6-nitroazolo[1,5-a]pyrimidines [30]. They are an even more specific class of heterocycles that have been explored much less thoroughly, although due to their nitro group, the variety of their properties is just as wide.

From the point of view of biological activity, these compounds exhibit antiviral [31,32], antiseptic [33,34], antioxidant [35,36], antitumor [37], and antiglycation activity [38]. From a synthetic point of view, the nitro groups are not only a quasi-form of the amino groups for creating azoloannelated purines [39–41], but they also, for example, open pathways for the modification of molecules by various nucleophiles [42,43]. Some useful azolo[1,5-a]pyrimidines are shown in Figure 1.
Previously we discovered the multicomponent reaction between aminoazoles, aromatic aldehydes, and 1-morpholino-2-nitroalkenes, which proceeds through different mechanisms depending on catalysis with Lewis [44] or Brønsted acids [45] (Scheme 1a,b). Formed that way, 4,7-dihydro-6-nitroazolo[1,5-a]pyrimidines have been obtained by the condensation of corresponding azoles with sodium salts of malonic dialdehyde [46] and the subsequent nucleophilic addition of π-extended (hetero)aromatic systems [43,47,48] (Scheme 1c). However, that approach has the following few disadvantages: a two-step synthesis procedure, an exclusively nucleophilic variant of structural modifications, and the limitation of possible modification positions. Moreover, the inability to aromatize 4,7-dihydro-6-nitroazolo[1,5-a]pyrimidines was established [49]. The method of “reductive autoaromatization” is used for oxidation, where the spontaneous aromatization of the heterocyclic system occurs during the reduction of the nitro group (Scheme 1c).

Thus, in this work we study the possibility of oxidation of 4,7-dihydro-6-nitroazolo[1,5-a]pyrimidines, while saving the nitro-group, and the reaction tolerance of the multicomponent reaction and oxidation process (Scheme 1d).
2. Results

To study the substrate scope, we carried out the multicomponent process by changing one of the initial reagents, while two were unchanged. Using 1-morpholino-2-nitropropylene 2b, benzaldehyde 3g with varying 3-aminoazoles 1 and molecular fragments in their structure in the medium BF$_3$·OEt$_2$–n-butanol, we obtained a series of 4,7-dihydro-6-nitro-7-phenylazolo[1,5-a]pyrimidines 4 in a moderate to good yield (Scheme 2).

The next goal of the work was to examine the obtained 4,7-dihydro-5-methyl-6-nitro-7-phenylazolo[1,5-a]pyrimidines 4. Using compound 4c as an example, we studied the effect of the nature of solvents and oxidants on the yield of the model reaction product. The results are shown in Table 1.

We found that the studied compound 4c decomposes under the action of the strong inorganic oxidizer (Table 1, № 1), and is not oxidized by atmospheric oxygen under acidic conditions (Table 1, № 2), as well as dichlorodicyanobenzoquinone (Table 1, № 3,4), Dess-Martin periodate (Table 1, № 5), and diacetoxyiodobenzene (Table 1, № 7). Nevertheless, the use of pyridinechlorochromate (Table 1, № 6) and diacetoxyiodobenzene (Table 1, № 8) in acetic acid at an elevated temperature leads to the formation of heterocycle 5c with the yields 49 and 81%, respectively.

Thereby, by using diacetoxyiodobenzene in acetic acid at a corresponding temperature, we obtained a number of new 6-nitro-5-methyl-7-phenylazolo[1,5-a]pyrimidines 5 in moderate to high yields (Scheme 3).
Thus, in the first part of the work, the possibility of the three-component reaction of 1-morpholino-2-nitropropylene 2a, benzaldehyde 3g, and 3-aminoazoles 1 was established with an assessment of the last reaction method. In addition, the oxidative aromatization of type 1 occurred. A feature of the tetrazolopyrimidine 5i is the formation of the azido-tetrazole tautomerism product 2-azido-5-nitro-6-methyl-4-phenylpyrimidine 5i', which was supported by IR spectroscopy data (see Supplementary Materials).

Table 1. Oxidation of 4c and reaction parameters.

| №  | Solvent | Oxidizing Agent | Temperature, °C | Reaction Time, h | Yield, % |
|----|---------|-----------------|-----------------|------------------|---------|
| 1  | H2O     | KMnO4, NaOH     | 25              | 1                | -       |
| 2  | TFA     | O2              | 25              | 10               | -       |
| 3  | CH2Cl2  | DDQ             | 25–40           | 5                | -       |
| 4  | MeCN    | DDQ             | 25–80           | 5                | Trace   |
| 5  | CH2Cl2  | DMP             | 25              | 5                | -       |
| 6  | AcOH    | PCC             | 50              | 5                | 49      |
| 7  | CH2Cl2  | PIDA            | 25–40           | 5                | -       |
| 8  | AcOH    | PIDA            | 100             | 1                | 81      |

The oxidation of triazolo- and tetrazolopyrimidines 4e–i occurs under harsher conditions than the pyrazolo- derivatives 4a–d; the process requires both a higher temperature and a longer reaction time. This is apparently due to the increasing π-deficient properties of five-membered heterocycles with the increasing numbers of N-atoms. A feature of the tetrazolopyrimidine 5i is the formation of the azido-tetrazole tautomerism product 2-azido-5-nitro-6-methyl-4-phenylpyrimidine 5i', which was supported by IR spectroscopy data (see Supplementary Materials).

Thus, in the first part of the work, the possibility of the three-component reaction of 1-morpholino-2-nitropropylene 2a, benzaldehyde 3g, and 3-aminoazoles 1 was established with an assessment of the last reaction method. In addition, the oxidative aromatization...
of type 4 dihydroazolopyrimidines, which was previously considered impossible, was realized.

![Scheme 3. Preparation of 6-nitro-5-methyl-7-phenylazolo[1,5-a]pyrimidines.](image)

The next stage of the study was the change the 1-morpholino-2-nitroalkene component 2. The number of synthetically available nitroalkenes 2 is limited, and all of them turned out to be reactive in the preparation of dihydronitro derivatives 6, which, in turn, were successfully dehydrogenated (Scheme 4).

![Scheme 4. Preparation of 4,7-dihydro-6-nitro-7-phenyl-5-R-pyrazolo[1,5-a]pyrimidines 6 and 4,7-dihydro-6-nitro-7-phenyl-5-R-pyrazolo[1,5-a]pyrimidines 7.](image)

Finally, we examined the effect of the structure of the third component, aldehydes, on the formation of 4,7-dihydro-6-nitroazolo[1,5-a]pyrimidines 8 and their subsequent oxidation. The object of study was to use benzaldehyde 3g and its derivatives with electron-donating 3c,d and electron-acceptor 3b groups, polycyclic anthracenecarbaldehyde 3e, heterocyclic thophenecarbaldehyde 3f, and propanal 3a. The use of the developed reaction conditions allowed us to obtain 7-R-5-methyl-6-nitropyrazolo[1,5-a]pyrimidines 8 in moderate to good yields (Scheme 5).
During the oxidation, we discovered that the interaction of heterocycle 8d with phenyliodozodiacetate, even at room temperature, leads to the resinification of the reaction mass. At the same time, the oxidation of heterocycles 8c and 8e was also accompanied by the formation of side products, but we have succeeded in isolating the desired compounds in yields of 24 and 30%, respectively. The results are presented in Scheme 6.

It was previously noted that it is impossible to obtain an aromatic system for similar structures, since attempts at oxidation have led either to unsuccessful results or to a mixture of unidentifiable products. However, results of this work complement the existing precedent since oxidation is complicated only in the case of compounds with an electron-donor substituent at position seven. During the oxidation of nitropyrazolopyrimidines 9e, besides the main product 9e, side products 9-acetoxy-anthracene 10 and anthraquinone 11 were also isolated using the flash chromatography method. These compounds were characterized in the composition of the mixture (Scheme 7).
Scheme 6. Preparation of 6-nitro-5-methyl-7-R-azolo[1,5-a]pyrimidines 9.

Scheme 7. Oxidation of 6-nitro-5-methyl-7-(anthracen-9-yl)azolo[1,5-a]pyrimidine 8e.

To elucidate the experimental data, we performed a quantum chemical calculation of the compounds 5a, 8a–e to obtain the charge distribution over the molecular structure. Figure 2 demonstrates the spin distribution of the highest occupied molecular orbital (HOMO) for compounds 8b and 8e. Other data are shown in the Supplementary Materials.
Indeed, the calculated data demonstrate that in compounds with an electron donating substituent 8e, the substituent is involved in the electron density distribution, which can have a serious influence on the direction of oxidation. Therefore, in these structures, the covalent bond between the C-7 atom and the substituent fissions and the nonstoichiometric formation of oxidation side products occurs.

Furthermore, the results of cyclic voltammetry also indicate the different behavior of compound 8 under oxidation conditions (Figure 3). Thus, for compound 8b, one irreversible peak of two-electron oxidation is observed. In turn, compound 8e is characterized by two peaks, apparently, of one-electron oxidation. The data for other compounds are given in the Supplementary Materials.

**Figure 2.** Visualization of HOMO for compounds 8b and 8e obtained in PBE0 approximation.

**Figure 3.** Cyclic voltammogram of 8b (blue) and 8e (red), 5 × 10⁻³ M.
Based on the results above and the literature’s data [50–52], it can be assumed that initially, for both compounds \(8b\) and \(8e\), single electron transfer (SET) occurs with the formation of an acetate-anion and a heterocyclic cation-radical 13 (Scheme 8). Then, the tautomeric transformation, the deprotonation of structure 14, and a shift of the hydrogen radical with the formation of radical particle 15 occur. Next, depending on the nature of the substituent, oxidation proceeds either with one more single electron transfer for compounds with an electron withdrawing substituent at position seven, or with the migration of a radical to a substituent for compounds with an electron donating substituent. Apparently, the intermediate 21 interacts with an oxygen molecule with the formation of carbonyl compound 23. Further intramolecular transformations lead to the homolytic fission of the covalent bond between the C-7 atom and the substituent in structure 24. The aromatic radical is either oxidized to anthraquinone 11 or is attacked by the acetoxy-radical from phenyliodozomonoacetate 18. The heterocyclic radical 25, apparently, decomposes nonstoichiometrically.

### Scheme 8. Plausible mechanism of oxidation of 6-nitro-5-methyl-7-R-azolo[1,5-a]pyrimidines 8.

#### 3. Materials and Methods

Unless stated otherwise, all solvents and commercially available reactants/reagents were used as received. Non-commercial starting materials were prepared as described
below or according to the literature’s procedures. One-dimensional $^1$H and $^{13}$C NMR spectra, as well as two-dimensional $^1$H-$^{13}$C HMBC experiments were acquired on a Bruker DRX-400 instrument (400 and 101 MHz, respectively) or a Bruker Avance NEO 600 instrument (600 and 151 MHz, respectively), equipped with a Prodigy broadband gradient cryoprobe, utilizing DMSO-$d_6$ and CDCl$_3$ as the solvent and TMS as the internal standard. IR spectra were recorded on a Bruker Alpha FTIR spectrometer equipped with a ZnSe ATR accessory. Mass spectra were recorded on a Shimadzu GCMS-QP2010 Ultra mass spectrometer, using EI method of ionization (70 eV). Elemental analysis was performed on a PerkinElmer 2400 CHN analyzer. The reaction progress was controlled by TLC on Silufol UV-254 plates, eluent—CH$_3$Cl. Melting points were determined on a Stuart SMP3 apparatus at the heating rate of 25 °C/min. 1-Morpholino-2-nitroethylenes 2 were prepared according to a literature procedure [53].

Density functional theory (DFT) simulation via Vienna Ab initio Simulation Package (VASP) [54] was performed for structural optimization of the molecules and obtaining of the charge distribution. The length of the supercell of every molecule was set to 22.5 Å and the cut-off energy of plane wave basis set was set to 750 eV. Structural optimization was performed using generalized gradient approximation (GGA) by Pedrew, Burke, and Ernzerhof (PBE) [55] for exchange-correlation potential. For all chemical species, projected augmented wave (PAW) pseudopotentials were used. The structures were optimized using two algorithms: conjugate gradient algorithm was implemented for initial optimization and after that RMM-DIIS (residual minimization scheme, direct inversion in the iterative subspace) algorithm was used for final optimization. The stopping criteria for optimization was $|F_i| \leq 0.01$ eV/Å, where $i = x, y, z$, i.e., absolute value of each force component acting on nuclei should be not greater than 10 meV/Å.

For PBE-optimized structures, a hybrid PBE0 simulation was performed to obtain charge distribution, for accounting of long-range interactions Grimme DFT-D3 corrections [56] were used. Since all the performed calculation were spin polarized, it was possible to extract spin density from the charge distribution. For the interpretation of the obtained data, the program VESTA [57] was used.

Cyclic voltammetry was carried out on a Metrohm Autolab PGSTAT128N potentiostat with a standard three-electrode configuration. Typically, a three electrodes cell equipped with a glass carbon working electrode, an Ag/AgNO$_3$ (0.01 M) reference electrode, and a glass carbon rod counter electrode was employed. The measurements were performed in acetonitrile with tetrabutylammonium hexafluorophosphate (0.1 M) as the supporting electrolyte under an argon atmosphere at a scan rate of 100 mV/s.

3.1. 4,7-dihydro-6-nitroazolo[1,5-a]pyrimidines 4,6,8; General procedure 1

To a suspension 2 mmol (1.0 equiv.) of corresponding aminoazole 1, 2 mmol (1.0 equiv.) of nitroalkene 2, and 2 mmol (1.0 equiv.) of aldehyde 3 in 5 mL of n-BuOH, was added 3 mmol (1.5 equiv., 0.37 mL) of BF$_3$·Et$_2$O. The reaction mixture was heated on oil bath at 120 °C for 2 h. The resulting solution was cooled to room temperature and stirred for 15 min. The obtained precipitate was filtered off, washed with 15 mL of i-PrOH. The precipitate was suspended in 50 mL of water, stirred for 5 min, filtered off again, and washed with 15 mL of water.

5-Methyl-6-nitro-7-phenyl-4,7-dihydropyrazolo[1,5-a]pyrimidine (4a). The reaction was performed according to the general procedure 1, employing 0.166 g (2 mmol, 1 equiv.) of 3-aminopyrazole 1a, 0.344 g (2 mmol, 1 equiv.) of 1-morpholino-2-nitropropane 2b and 0.20 mL (2 mmol, 1 equiv.) of benzaldehyde 3g. Yellow solid. Yield, 0.266 g (52%); mp, 244–247 °C. IR (ATR): 1516, 1415 (NO$_2$). $^1$H NMR (400 MHz, DMSO-$d_6$): $\delta = 2.63$ (3H, s, CH$_3$); 5.48 (1H, s, H-7); 7.09–7.28 (5H, m, Ph); 7.41 (1H, s, H-2); 10.74 (1H, s, NH); 12.37 (1H, s, H-3). $^{13}$C ($^1$H) NMR (101 MHz, DMSO-$d_6$): $\delta = 21.9; 39.5; 106.8; 122.8; 126.0; 126.3; 126.5; 126.5; 139.0; 144.4; 146.7; 151.6. Anal. Calcd for C$_{13}$H$_7$N$_4$O$_2$: C, 60.93; H, 4.72; N, 21.86. Found: C, 60.80; H, 4.65; N, 21.90.
2,5-Dimethyl-6-nitro-7-phenyl-4,7-dihydropyrazolo[1,5-alpyrimidine (4b). The reaction was performed according to the general procedure 1, employing 0.194 g (2 mmol, 1 equiv.) of 3-amino-5-methylpyrazole 1b, 0.344 g (2 mmol, 1 equiv.) of 1-morpholin-2-nitropyrrole 2b, and 0.20 mL (2 mmol, 1 equiv.) of benzaldehyde 3g. Yellow solid. Yield, 0.221 g (46%); mp, 127.3; 128.4; 128.5; 139.5; 145.5; 149.1; 159.3. Anal. Calcd for C_{13}H_{11}N_{3}O_2: C, 57.49; H, 4.90; N, 25.75. Found: C, 57.49; H, 4.90; N, 25.75.

3-Ethoxycarbonyl-5-methyl-6-nitro-7-phenyl-4,7-dihydropyrazolo[1,5-alpyrimidine (4c). The reaction was performed according to the general procedure 1, employing 0.168 g (2 mmol, 1 equiv.) of 3-amino-5-methyl-1,2,4-triazole 1c, 0.344 g (2 mmol, 1 equiv.) of 1-morpholin-2-nitropyrrole 2b, and 0.20 mL (2 mmol, 1 equiv.) of benzaldehyde 3g. Bright yellow solid. Yield, 0.37 mL (44%); mp, 122.6; 127.2; 128.4; 128.6; 137.4; 139.6; 148.1; 150.9. Anal. Calcd for C_{13}H_{11}N_{3}O_2: C, 56.10; H, 4.26; N, 27.27. Found: C, 56.03; H, 4.91; N, 17.06. Found: C, 58.41; H, 4.81; N, 19.17.

3-Cyano-5-methyl-2-methylthio-6-nitro-7-phenyl-4,7-dihydropyrazolo[1,5-alpyrimidine (4d). The reaction was performed according to the general procedure 1, employing 0.196 g (2 mmol, 1 equiv.) of 3-amino-4-cyano-5-methylthiopyrazole 1d, 0.310 g (2 mmol, 1 equiv.) of 1-morpholino-2-nitropropylene 2b, and 0.20 mL (2 mmol, 1 equiv.) of benzaldehyde 3g. Light yellow solid. Yield, 0.426 g (65%); mp, 157.5; 161.7. Anal. Calcd for C_{13}H_{11}N_{3}O_2S: C, 55.04; H, 4.00; N, 21.39. Found: C, 55.00; H, 3.98; N, 21.39.

5-Methyl-6-nitro-7-phenyl-4,7-dihydro-1,2,4-triazolo[1,5-alpyrimidine (4e). The reaction was performed according to the general procedure 1, employing 0.168 g (2 mmol, 1 equiv.) of 3-amino-4-etoxycarbonylpyrazole 1e, 0.344 g (2 mmol, 1 equiv.) of 1-morpholin-2-nitropyrrole 2b, and 0.20 mL (2 mmol, 1 equiv.) of benzaldehyde 3g. Light yellow solid. Yield, 0.231 g (44%); mp, 126.0; 127.0; 128.1; 135.5; 144.7; 145.8; 151.2. Anal. Calcd for C_{13}H_{11}N_{3}O_2: C, 56.03; H, 4.91; N, 25.82. Found: C, 56.10; H, 4.90; N, 25.82.

2,5-Dimethyl-6-nitro-7-phenyl-4,7-dihydropyrazolo[1,5-alpyrimidine (4f). The reaction was performed according to the general procedure 1, employing 0.194 g (2 mmol, 1 equiv.) of 3-amino-5-methyl-1,2,4-triazole 1f, 0.344 g (2 mmol, 1 equiv.) of 1-morpholin-2-nitropyrrole 2b, and 0.20 mL (2 mmol, 1 equiv.) of benzaldehyde 3g. Yellow solid. Yield, 0.238 g (44%); mp, 125 C with decomp. IR (ATR): 1586, 1314 (NO_2). 1H NMR (400 MHz, DMSO-d_6): δ = 1.32 (3H, t, CH_2-CH_3, J = 7.1 Hz); 2.79 (3H, s, C-5-CH_3); 4.27 (2H, dd, CH_2N); 6.53 (1H, s, H-7); 7.26–7.38 (5H, m, Ph); 7.66 (1H, s, H-2); 10.29 (1H, s, NH). 13C [1H] NMR (101 MHz, DMSO-d_6): δ = 14.3; 19.8; 59.5; 59.8; 97.5; 122.6; 127.2; 128.4; 128.6; 137.4; 139.6; 140.8; 148.1; 161.7. Anal. Calcd for C_{15}H_{13}N_{3}O_2: C, 58.53; H, 4.91; N, 20.73. Found: C, 58.28; H, 5.26; N, 20.65.

3-Ethoxycarbonyl-5-methyl-6-nitro-7-phenyl-4,7-dihydropyrazolo[1,5-alpyrimidine (4g). To a suspension of 0.304 g (2 mmol, 1 equiv.) of 3-amino-5-trifluoromethyl-1,2,4-triazole 1g, 0.344 g (2 mmol, 1 equiv.) of 1-morpholin-2-nitropyrrole 2b and 0.20 mL (2 mmol, 1 equiv.) of benzaldehyde 3g in 5 mL of n-BuOH was added 3 mmol (1.5 equiv., 0.37 mL) of BF_3·Et_2O. The reaction mixture was heated on oil bath at 120 °C for 2 h. The resulting solution was cooled to room temperature, and 5 mL of n-heptane was added. The obtained suspension was stirred for 10 min, filtered off, and washed with 20 mL of water.
The product was recrystallized from i-PrOH-H₂O 1/1. Yellow solid. Yield, 0.273 g (42%); mp, 231–234 °C. IR (ATR): 1573, 1321 (NO₂). ¹H NMR (400 MHz, DMSO-d₆): δ = 2.66 (3H, s, C-5-CH₃); 6.74 (1H, s, H-7); 7.31–7.45 (5H, m, Ph); 12.13 (1H, s, NH). ¹³C [¹H] NMR (101 MHz, DMSO-d₆): δ = 20.1; 60.4; 118.9 (q, J = 269.7 Hz); 122.5; 127.6; 128.7; 128.9; 138.4; 147.0; 148.8; 151.1 (q, J = 39.1 Hz). Anal. Calcd for C₁₃H₁₀F₃N₃O₂: C, 48.01; H, 3.10; N, 21.53. Found: C, 48.15; H, 3.24; N, 21.40.

5-Methyl-2-methylthio-6-nitro-7-phenyl-4,7-dihydro-1,2,4-triazolo[1,5-alpyrimidine (4h). The reaction was performed according to the general procedure 1, employing 0.260 g (2 mmol, 1 equiv.) of 3-amino-5-methylthio-1,2,4-triazole 1h, 0.344 g (2 mmol, 1 equiv.) of 1-morpholino-2-nitropropylene 2b, and 0.20 mL (2 mmol, 1 equiv.) of benzaldehyde 3g. Pale yellow solid. Yield, 0.388 g (64%); mp, 273–276 °C. IR (ATR): 1557, 1320 (NO₂). ¹H NMR (400 MHz, DMSO-d₆): δ = 2.42 (3H, s, S-CH₃); 2.64 (3H, s, C-5-CH₃); 6.56 (1H, s, H-7); 7.27–7.38 (5H, m, Ph); 11.90 (1H, s, NH). ¹³C [¹H] NMR (101 MHz, DMSO-d₆): δ = 13.5; 20.2; 59.8; 122.2; 127.4; 128.5; 128.6; 139.1; 146.2; 148.8; 160.0. Anal. Calcd for C₁₃H₁₁N₅O₂S: C, 51.49; H, 4.41; N, 23.02. Found: C, 51.47; H, 4.32; N, 23.09.

5-Methyl-6-nitro-7-phenyl-4,7-dihydropyrazotrazolo[1,5-alpyrimidine (4i). The reaction was performed according to the general procedure 1, employing 0.206 g (2 mmol, 1 equiv.) of 3-aminotetrazole monohydrate 1i, 0.344 g (2 mmol, 1 equiv.) of 1-morpholino-2-nitropropylene 2b, and 0.20 mL (2 mmol, 1 equiv.) of benzaldehyde 3g. To a suspension of 0.206 g (2 mmol, 1 equiv.) of 3-aminotetrazole monohydrate 1i, 0.344 g (2 mmol, 1 equiv.) of 1-morpholino-2-nitropropylene 2b and 0.20 mL (2 mmol, 1 equiv.) of benzaldehyde 3g in 5 mL of n-BuOH was added 3 mmol (1.5 equiv., 0.37 mL) of BF₃·OEt₂. The reaction mixture was heated on oil bath at 120 °C for 2 h. The resulting solution was cooled to room temperature, and 5 mL of n-heptane was added. The obtained suspension was stirred for 10 min, decanted, and 5 mL of i-PrOH was added. The obtained suspension was filtered off and washed with 20 mL of water. The product was recrystallized from i-PrOH. White yellow solid. Yield, 0.237 g (46%); mp, 236–239 °C. IR (ATR): 1576, 1295 (NO₂). ¹H NMR (400 MHz, CDCl₃): δ = 2.68 (3H, s, S-CH₃); 7.02 (1H, s, H-7); 7.30–7.50 (5H, m, Ph); 12.30 (1H, s, NH). ¹³C [¹H] NMR (101 MHz, CDCl₃): δ = 20.2; 58.9; 122.2; 127.5; 128.9; 129.1; 138.2; 147.4; 149.4. Anal. Calcd for C₁₁H₁₀N₆O₂: C, 51.16; H, 3.90; N, 32.54. Found: C, 51.10; H, 3.95; N, 32.51.

3.2. 6-Nitrozazolo[1,5-alpyrimidines 5,7,9; General procedure 2

To a suspension of 100 mg of corresponding heterocycle 4,6,8 in 5 mL of acetic acid, 1.25 equiv. of PhI(OAc)₂ was added. The reaction mixture was heated on oil bath at 100 °C for pyrazolopyrimidines and 130 °C for tetra- and triazolopyrimidines for 1.5 h and 4 h, respectively. To the resulting solution, another 0.5 equiv. of PhI(OAc)₂ was added and stirred for 30 min. After this, 5 mL of EtOH was added and stirred again for 15 min. After heating, the resulting solution was concentrated under reduced pressure. To the residue, 3 mL of n-heptane was added and evaporated again. The residue was purified using flash-chromatography on silica gel 60 with CHCl₃ as the eluent to give the desirable product.

5-Methyl-6-nitro-7-phenylpyrazolozolo[1,5-alpyrimidine (5a). The reaction was performed according to the general procedure 2, employing 0.39 mmol of heterocycle 4a and 0.157 + 0.063 g (0.48 + 0.19 mmol) of PhI(OAc)₂. Sand color solid. Yield, 69 mg (70%); mp, 232–235 °C. IR (ATR): 1527, 1364 (NO₂). ¹H NMR (400 MHz, CDCl₃): δ = 2.80 (3H, s, CH₃); 7.48–7.62 (5H, m, Ph); 8.03 (1H, s, H-2); 12.05 (1H, s, H-3). ¹³C [¹H] NMR (101 MHz, CDCl₃): δ = 21.8; 113.3; 128.4; 129.7; 130.7; 132.3; 135.7; 138.2; 142.8; 150.6; 151.5. Anal. Calcd for C₁₃H₁₀N₆O₂: C, 61.41; H, 3.96; N, 22.04. Found: C, 61.44; H, 3.93; N, 22.00.

2,5-Dimethyl-6-nitro-7-phenylpyrazolozolo[1,5-alpyrimidine (5b). The reaction was performed according to the general procedure 2, employing 0.39 mmol of heterocycle 4a and 0.150 + 0.060 g (0.47 + 0.19 mmol) of PhI(OAc)₂. Sand color solid. Yield, 69 mg (55%); mp, 199–212 °C. IR (ATR): 1525, 1367 (NO₂). ¹H NMR (400 MHz, CDCl₃): δ = 2.04 (3H, s, C-2-CH₃); 2.77 (3H, s, C-5-CH₃); 2.73–2.78 (5H, m, Ph); 11.61 (1H, br.s., NH). ¹³C [¹H] NMR
Molecules 2021, 26, 4719

(101 MHz, CDCl₃): δ = 14.4; 21.5; 111.5; 128.5; 128.7; 129.9; 131.3; 139.2; 143.0; 144.7; 150.5; 151.1. Anal. Calcd for C₁₅H₁₂N₂O₂: C, 62.68; H, 4.51; N, 20.88. Found: C, 62.75; H, 4.43; N, 20.82.

3-Ethoxycarbonyl-5-methyl-6-nitro-7-phenylpyrazolo[1,5-alpyrimidin (5c). The reaction was performed according to the general procedure 2, employing 0.30 mmol of heterocycle 4c and 0.123 + 0.049 (0.38 + 0.15 mmol) of PhI(OAc)₂. Pale yellow solid. Yield, 64 mg (65%). mp, 147–150 °C. IR (ATR): 1714 (C=O); 1534, 1364 (NO₂). ¹H NMR (400 MHz, CDCl₃): δ = 1.42 (3H, t, CH₃-CH₂-); 2.79 (3H, s, C-5-CH₃); 3.44 (2H, q, CH₂-CH₃), J = 7.2, 2.5 Hz); 7.55–7.71 (5H, m, Ph). 13C [¹H] NMR (101 MHz, CDCl₃): δ = 14.8; 22.4; 61.1; 104.5; 125.5; 129.3; 129.5; 132.6; 137.6; 142.5; 147.2; 150.1; 154.9; 162.2. Anal. Calcd for C₁₅H₁₂N₂O₂: C, 56.53; H, 3.49; N, 27.44. Found: C, 56.54; H, 4.44; N, 27.49.

5-Methyl-6-nitro-7-phenyl-1,2,4-triazolo[1,5-alpyrimidin (5e). The reaction was performed according to the general procedure 2, employing 0.39 mmol of heterocycle 4i and 0.149 + 0.059 (0.46 + 0.18 mmol) of PhI(OAc)₂. Pale orange solid. Yield, 49 mg (50%). mp, 180–183 °C. IR (ATR): 1542, 1368 (NO₂). ¹H NMR (400 MHz, CDCl₃): δ = 2.80 (3H, s, CH₃); 7.58–7.72 (5H, m, Ph). 13C [¹H] NMR (101 MHz, CDCl₃): δ = 13.8; 22.1; 83.3; 111.7; 125.1; 139.2; 142.4 (C=O); 137.4; 141.9; 150.8; 155.5; 162.4. Anal. Calcd for C₁₅H₁₁N₃O₂: C, 55.38; H, 3.41; N, 27.45. Found: C, 55.34; H, 3.49; N, 27.49.

2,5-Dimethyl-6-nitro-7-phenyl-1,2,4-triazolo[1,5-alpyrimidin (5f). The reaction was performed according to the general procedure 2, employing 0.30 mmol of heterocycle 4f and 0.149 + 0.059 (0.46 + 0.18 mmol) of PhI(OAc)₂. Beige solid. Yield, 64 mg (65%). mp, 151, 1349 (NO₂). ¹H NMR (400 MHz, CDCl₃): δ = 2.55 (3H, s, S-CH₃), 2.72 (3H, s, C-5-CH₃); 7.2, 2.5 Hz); 7.55–7.71 (5H, m, Ph); 8.59 (1H, s, H-2). 13C [¹H] NMR (101 MHz, CDCl₃): δ = 22.3; 125.3; 129.2; 129.7; 133.0; 137.8; 143.0; 154.4; 157.8; 158.7. Anal. Calcd for C₁₆H₁₅N₄O₂: C, 62.68; H, 4.51; N, 20.88. Found: C, 62.75; H, 4.43; N, 20.82.

5-Methyl-6-nitro-7-phenyl-1,2,4-triazolo[1,5-alpyrimidin (5g). The reaction was performed according to the general procedure 2, employing 0.30 mmol of heterocycle 4g and 0.124 + 0.050 (0.38 + 0.15 mmol) of PhI(OAc)₂. White yellow solid. Yield, 64 mg (65%). mp, 172–175 °C. IR (ATR): 1548, 1367 (NO₂). ¹H NMR (400 MHz, CDCl₃): δ = 2.88 (3H, s, C-5-CH₃); 7.59–7.74 (5H, m, Ph). 13C [¹H] NMR (101 MHz, CDCl₃): δ = 15.7; 22.2; 125.6; 129.2; 129.6; 132.8; 137.4; 142.2; 154.9; 157.0; 169.6. Anal. Calcd for C₁₅H₁₁N₅O₂: C, 57.99; H, 4.12; N, 26.01. Found: C, 58.04; H, 4.20; N, 25.93.

5-Methyl-6-nitro-7-phenyl-2-trifluoromethyl-1,2,4-triazolo[1,5-alpyrimidin (5h). The reaction was performed according to the general procedure 2, employing 0.30 mmol of heterocycle 4h and 0.133 + 0.053 (0.41 + 0.17 mmol) of PhI(OAc)₂. Beige solid. Yield, 39 mg (40%). mp, 193–198 °C. IR (ATR): 1542, 1369 (NO₂). ¹H NMR (400 MHz, CDCl₃): δ = 2.81 (3H, s, C-5-CH₃); 3.12 (3H, s, S-CH₃); 7.56–7.73 (5H, m, Ph). 13C [¹H] NMR (101 MHz, CDCl₃): δ = 22.5; 119.0 (q, J = 271.7 Hz); 124.3; 129.4; 129.8; 133.5; 138.7; 143.6; 154.6; 159.8; 159.9 (q, J = 40.5 Hz). Anal. Calcd for C₁₃H₈F₃N₅O₂: C, 48.31; H, 2.49; N, 21.67. Found: C, 48.36; H, 2.52; N, 21.61.

5-Methyl-2-methylthio-6-nitro-7-phenyl-1,2,4-triazolo[1,5-alpyrimidin (5i). The reaction was performed according to the general procedure 2, employing 0.30 mmol of heterocycle 4i and 0.156 + 0.062 g (0.48 + 0.19 mmol) of PhI(OAc)₂. White yellow solid. Yield, 44 mg (45%). mp, 118–120 °C. IR (ATR): 2143 (N₃); 1519, 1329 (NO₂). ¹H NMR (400 MHz, CDCl₃): δ = 2.59 (3H, s, CH₃); 7.43–7.70 (5H, m, Ph). 13C [¹H] NMR (101 MHz, CDCl₃): δ = 21.0; 128.4; 159.5; 132.1; 133.4;
6-Nitro-7-phenyl-4,7-dihydropyrazolo[1,5-alpyrimidine (6a). The reaction was performed according to the general procedure 1, employing 0.166 g (2 mmol, 1 equiv.) of 3-aminopyrazole 1a, 0.316 g (2 mmol, 1 equiv.) of 1-morpholino-2-nitroethylene 2a, and 0.20 mL (2 mmol, 1 equiv.) of benzaldehyde 3g. Yellow solid. Yield, 0.387 g (80%); mp, 289–295 °C. IR (ATR): 1528, 1417 (NO2). 1H NMR (400 MHz, DMSO-d6): δ = 5.43 (1H, s, H-7); 7.10–7.30 (5H, m, Ph); 7.41 (1H, s, H-2); 8.36 (1H, d, H-5, J = 6.1 Hz); 10.88 (1H, d, NH, J = 6.4 Hz); 12.45 (1H, s, H-3). 13C [1H] NMR (101 MHz, DMSO-d6): δ = 38.2; 106.8; 124.3; 126.5; 128.4; 127.3; 139.0; 144.2; 146.0. Anal. Calcd for C15H13N4O2: C, 59.50; H, 4.16; N, 23.13. Found: C, 59.61; H, 4.20; N, 23.01.

5-Ethyl-6-nitro-7-phenyl-4,7-dihydropyrazolo[1,5-alpyrimidine (6b). The reaction was performed according to the general procedure 1, employing 0.166 g (2 mmol, 1 equiv.) of 3-aminopyrazole 1a, 0.372 g (2 mmol, 1 equiv.) of 1-morpholino-2-nitroacrylate 2c, and 0.20 mL (2 mmol, 1 equiv.) of benzaldehyde 3g. Green yellow solid. Yield, 0.243 (45%); mp, 231–234 °C. IR (ATR): 1511, 1426 (NO2). 1H NMR (400 MHz, DMSO-d6): δ = 1.29 (3H, t, CH2, J = 7.2 Hz); 2.90–3.05 (2H, m, CH2); 5.48 (1H, s, H-7); 7.09–7.32 (5H, m, Ph); 7.41 (1H, s, H-2); 10.73 (1H, s, NH); 12.37 (1H, s, H-3). 13C [1H] NMR (101 MHz, DMSO-d6): δ = 8.13; 27.3; 39.5; 106.8; 122.1; 122.1; 126.0; 126.2; 126.4; 144.3; 146.8; 156.4. Anal. Calcd for C14H12N4O2: C, 52.21; H, 5.22; N, 20.73. Found: C, 52.28; H, 5.18; N, 20.65.

6-Nitro-7-phenylpyrazolo[1,5-alpyrimidine (7a). The reaction was performed according to the general procedure 2, employing 0.41 mmol of heterocycle 6a and 0.166 + 0.067 g (0.52 + 0.21 mmol) of Ph(0Ac)2. Light orange solid. Yield, 75 mg (76%); mp, 205–213 °C. IR (ATR): 1523, 1338 (NO2). 1H NMR (400 MHz, CDCl3): δ = 7.46–7.60 (5H, m, Ph); 8.10 (1H, s, H-2); 9.25 (1H, d, H-5); 12.24 (1H, s, H-3). 13C [1H] NMR (101 MHz, CDCl3): δ = 115.6; 128.4; 129.5; 130.4; 132.8; 136.7; 140.1; 141.5; 146.4; 152.1. Anal. Calcd for C12H12N4O2: C, 60.00; H, 3.36; N, 23.32. Found: C, 59.99; H, 3.28; N, 23.40.

5-Ethyl-6-nitro-7-phenylpyrazolo[1,5-alpyrimidine (7b). The reaction was performed according to the general procedure 2, employing 0.37 mmol of heterocycle 6b and 0.149 + 0.060 g (0.46 + 0.19 mmol) of Ph(0Ac)2. Pale yellow solid. Yield, 69 mg (70%); mp, 198–205 °C. IR (ATR): 1522, 1341 (NO2). 1H NMR (400 MHz, CDCl3): δ = 1.53 (3H, t, CH2, J = 7.5 Hz); 3.08 (2H, q, CH2, J = 7.5 Hz); 7.50–7.60 (5H, m, Ph); 8.06 (1H, s, H-2); 12.75 (1H, s, H-3). 13C [1H] NMR (101 MHz, CDCl3): δ = 13.5; 28.0; 113.3; 128.4; 129.7; 130.6; 132.4; 135.6; 138.1; 142.6; 150.8; 156.0. Anal. Calcd for C14H12N4O2: C, 62.68; H, 4.51; N, 20.88. Found: C, 62.61; H, 4.54; N, 20.81.

7-Ethyl-6-nitro-5-methyl-4,7-dihydropyrazolo[1,5-alpyrimidine (8a). The reaction was performed according to the general procedure 1, employing 0.166 g (2 mmol, 1 equiv.) of 3-aminopyrazole 1a, 0.344 g (2 mmol, 1 equiv.) of 1-morpholino-2-nitropropylene 2b, and 0.14 mL (2 mmol, 1 equiv.) of propionaldehyde 3a. Reaction mixture was heated in a glass autoclave. Orange solid. Yield, 0.175 g (42%); mp, 235 °C with decomp. IR (ATR): 1515, 1278 (NO2). 1H NMR (400 MHz, DMSO-d6): δ = 0.72 (3H, t, CH2-CH3, J = 7.4 Hz); 1.45–1.65 (2H, m, CH2-CH3); 4.23–4.34 (1H, m, H-7); 7.54 (1H, s, H-2); 10.54 (1H, s, NH); 12.36 (1H, s, H-3). 13C [1H] NMR (101 MHz, DMSO-d6): δ = 9.8; 21.9; 28.4; 34.4; 105.0; 122.6; 125.9; 145.7; 152.0. Anal. Calcd for C9H12N4O2: C, 51.92; H, 5.81; N, 26.91. Found: C, 52.08; H, 5.92; N, 26.75.

6-Nitro-5-methyl-7-(4′-nitrophenyl)-4,7-dihydropyrazolo[1,5-alpyrimidine (8b). To a suspension of 0.166 g (2 mmol, 1 equiv.) of 3-aminopyrazole 1a, 0.344 g (2 mmol, 1 equiv.) of 1-morpholino-2-nitropropylene 2b in 5 mL of n-BuOH, 3 mmol (1.5 equiv., 0.37 mL) of BF3·Et2O was added. The reaction mixture was heated on oil bath at 120 °C for 15 min. To the obtained solution, 0.302 g (2 mmol, 1 equiv.) of 4-nitrobenzaldehyde 3b was added. The reaction mixture was heated on oil bath at 120 °C for 2 h. The resulting solution was cooled to room temperature and stirred for 15 min. The obtained precipitate was filtered off and washed with 15 mL of i-PrOH. The precipitate was suspended in 50 mL of water, stirred for 5 min, filtered off again, and washed with 15 mL of water. To the residue, 20 mL
of 2 M Na₂CO₃ and 50 mL of water were added and stirred for 20 min. The solution was extracted twice with 20 mL of EtOAc. To the water phase, 15 mL of hexane was added, and the mixture was neutralized by diluted HCl to pH 7. The resulting mixture was stirred overnight, filtered off, and washed with water. Yellow solid. Yield, 0.355 g (59%); mp, 197 °C with decomp.

IR (ATR): 1535, 1352 (NO₂); 1508, 1268 (NO₂). ¹H NMR (600 MHz, DMSO-d₆): δ = 2.66 (3H, s, C-5-CH₃); 5.64 (1H, s, H-5); 7.45 (1H, s, H-2); 7.50 (2H, d, H-2'; J = 8.3 Hz); 8.12 (2H, d, H-3', J = 8.3 Hz); 10.95 (1H, s, NH); 12.49 (1H, s, H-3). ¹³C [¹H] NMR (151 MHz, DMSO-d₆): δ = 22.0; 39.8; 105.6; 121.8; 123.8; 127.0; 144.2; 145.9; 152.5; 154.1. Anal. Calcd for C₁₅H₁₁N₄O₂: C, 51.83; H, 3.68; N, 23.25. Found: C, 51.89; H, 3.73; N, 23.19.

6-Nitro-5-methyl-7-(4'-metoxyphenyl)-4,7-dihydropyrazolo[1,5-alpyrimidaine (8e). The reaction was performed according to the general procedure 1, employing 0.166 g (2 mmol, 1 equiv.) of 3-aminopyrazole 1a, 0.344 g (2 mmol, 1 equiv.) of 1-morpholino-2-nitropropylene 2b, and 0.24 mL (2 mmol, 1 equiv.) of 4-metoxybenzaldehyde 3c. Yellow solid. Yield, 0.355 (62%); mp, 264–266 °C. IR (ATR): 1509, 1260 (NO₂). ¹H NMR (600 MHz, DMSO-d₆): δ = 2.61 (3H, s, C-5-CH₃); 3.68 (3H, s, O-CH₃); 5.43 (1H, s, H-5); 6.80 (2H, d, H-3', J = 8.7 Hz); 7.10 (2H, d, H-2', J = 8.7 Hz); 7.39 (1H, s, H-2); 10.72 (1H, s, NH); 12.37 (1H, s, H-3). ¹³C [¹H] NMR (151 MHz, DMSO-d₆): δ = 22.0; 38.7; 55.0; 107.1; 113.7; 123.3; 126.7; 139.0; 144.5; 151.2; 157.6. Anal. Calcd for C₁₄H₁₄N₄O₃: C, 58.74; H, 4.93; N, 19.57. Found: C, 58.78; H, 4.91; N, 19.61.

6-Nitro-5-methyl-7-(4'-hydroxy-3'-metoxyphenyl)-4,7-dihydropyrazolo[1,5-alpyrimidaine (8d). The reaction was performed according to the general procedure 1, employing 0.166 g (2 mmol, 1 equiv.) of 3-aminopyrazole 1a, 0.344 g (2 mmol, 1 equiv.) of 1-morpholino-2-nitropropylene 2b, and 0.24 g (2 mmol, 1 equiv.) of 4-hydroxy-3-metoxybenzaldehyde 3d. Yellow solid. Yield, 0.314 (52%); mp, 224-226 °C. IR (ATR): 3170 (OH); 1515, 1264 (NO₂). ¹H NMR (400 MHz, DMSO-d₆): δ = 2.61 (3H, s, C-5-CH₃); 3.73 (3H, s, O-CH₃); 5.39 (1H, s, H-5); 6.50 (1H, dd, H-5'); 8.17 (1H, s, H-2); 10.72 (1H, s, NH); 12.37 (1H, s, H-3). ¹³C [¹H] NMR (151 MHz, DMSO-d₆): δ = 21.8; 38.9; 55.6; 107.2; 111.0; 115.3; 118.1; 123.0; 126.3; 137.9; 144.3; 144.8; 147.4; 151.1. Anal. Calcd for C₁₄H₁₄N₄O₃: C, 55.63; H, 4.67; N, 18.53. Found: C, 55.69; H, 4.71; N, 18.50.

6-Nitro-5-methyl-7-(anthracene-9'-yl)-4,7-dihydropyrazolo[1,5-alpyrimidaine (8e). The reaction was performed according to the general procedure 1, employing 0.166 g (2 mmol, 1 equiv.) of 3-aminopyrazole 1a, 0.344 g (2 mmol, 1 equiv.) of 1-morpholino-2-nitropropylene 2b, and 0.412 g (2 mmol, 1 equiv.) of 9-anthraldehyde 3e. The product was recrystallized from n-ButOH. The substance was dried over P₂O₅ at 140 °C. Pale green solid. Yield, 0.363 (51%); mp, 222 °C with decomp. IR (ATR): 1522, 1290 (NO₂). ¹H NMR (400 MHz, DMSO-d₆): δ = 2.66 (3H, s, C-5-CH₃); 7.02 (1H, s, H-5); 7.13 (1H, s, H-10'); 7.29–7.40 (2H, m, H-3', H-6); 7.50–7.67 (2H, m, H-2', H-7'); 8.03 (1H, d, H-1', J = 8.3 Hz); 8.05–8.15 (2H, m, H-4', H-5'); 8.46 (1H, s, H-2); 8.79 (1H, d, H-8', J = 9.0 Hz); 11.01 (1H, s, NH); 12.32 (1H, s, H-3). ¹³C [¹H] NMR (151 MHz, DMSO-d₆): δ = 21.7; 34.1; 106.4; 123.7; 124.1; 124.4; 124.9; 125.0 (2C); 126.3; 126.4; 128.6; 128.9; 129.5; 131.0; 131.7; 136.9; 144.7; 150.5. Anal. Calcd for C₂₁H₁₆N₄O₂: C, 70.77; H, 4.53; N, 15.72. Found: C, 70.74; H, 4.51; N, 15.76.

6-Nitro-5-methyl-7-(thiophen-2'-yl)-4,7-dihydropyrazolo[1,5-alpyrimidaine (8f). The reaction was performed according to the general procedure 1, employing 0.166 g (2 mmol, 1 equiv.) of 3-aminopyrazole 1a, 0.344 g (2 mmol, 1 equiv.) of 1-morpholino-2-nitropropylene 2b, and 0.184 mL (2 mmol, 1 equiv.) of thiophen-2-carbaldehyde 3d. Pale green solid. Yield, 0.278 (53%); mp, 208 °C with decomp. IR (ATR): 1511, 1256 (NO₂). ¹H NMR (400 MHz, DMSO-d₆): δ = 2.58 (3H, s, C-5-CH₃); 5.84 (1H, s, H-7); 6.80–6.82 (1H, m, H-3'); 6.83–6.87 (1H, m, H-4'); 7.23 (1H, d, H-5', J = 5.0 Hz); 7.56 (1H, s, H-2); 10.85 (1H, s, NH); 12.49 (1H, s, H-3). ¹³C [¹H] NMR (101 MHz, DMSO-d₆): δ = 21.8; 34.3; 106.2; 122.9; 123.1; 123.6; 126.5; 126.7; 144.5; 150.6; 151.1. Anal. Calcd for C₁₁H₁₀N₄O₂: C, 50.37; H, 3.84; N, 21.36. Found: C, 50.20; H, 3.99; N, 21.49.
7-Ethyl-6-nitro-5-methylpyrazolo[1,5-a]pyrimidine (9a). The reaction was performed according to the general procedure 2, employing 0.48 mmol of heterocycle 8a and 0.194 + 0.077 g (0.60 + 0.24 mmol) of PhI(OAc)$_2$. White yellow solid. Yield, 49 mg (50%); mp, 175–179 °C. IR (ATR): 1521, 1360 (NO$_2$). $^1$H NMR (400 MHz, CDCl$_3$): $\delta$ = 1.42 (3H, t, CH$_2$-CH$_3$, $J$ = 7.6 Hz); 2.76 (3H, s, C-5-CH$_3$); 1.42 (2H, q, CH$_2$-CH$_3$, $J$ = 6.6 Hz); 8.23 (1H, s, H-2); 13.02 (1H, s, H-10). $^{13}$C $[^1]$H NMR (101 MHz, CDCl$_3$): $\delta$ = 15.1; 21.9; 23.6; 113.4; 134.5; 141.9; 143.6; 150.5; 151.4. Anal. Calcd for C$_{21}$H$_{12}$N$_4$O$_2$: C, 52.42; H, 4.89; N, 27.17. Found: C, 52.39; H, 4.89; N, 27.20.

6-Nitro-5-methyl-7-(4′-nitrophenyl)-pyrazolo[1,5-a]pyrimidine (9b). The reaction was performed according to the general procedure 2, employing 0.33 mmol of heterocycle 8b and 0.134 + 0.054 g (0.42 + 0.17 mmol) of PhI(OAc)$_2$. Pale yellow solid. Yield, 49 mg (50%); mp, 243 °C with decomp. IR (ATR): 1542, 1344 (NO$_2$). $^1$H NMR (400 MHz, DMSO-d$_6$): $\delta$ = 2.68 (3H, s, C-5-CH$_3$); 7.82 (2H, d, H-2, $J$ = 8.6 Hz); 8.09 (1H, s, H-2); 8.41 (2H, d, H-3′, $J$ = 8.6 Hz); 14.26 (1H, s, H-3). $^{13}$C $[^1]$H NMR (101 MHz, DMSO-d$_6$): $\delta$ = 21.5; 111.6; 124.3; 129.6; 134.2; 135.0; 140.8; 148.3; 150.1; 150.2. Anal. Calcd for C$_{19}$H$_{14}$N$_4$O$_2$: C, 52.18; H, 3.03; N, 23.40. Found: C, 52.25; H, 2.99; N, 23.38.

6-Nitro-5-methyl-7-(anthracene-9′-yl)-pyrazolo[1,5-a]pyrimidine (9e), 9-acetoxy-10-oxoanthracene (10), anthraquinone (11). The reaction was performed according to the general procedure 2, employing 0.28 mmol of heterocycle 8e and 0.113 + 0.045 g (0.35 + 0.14 mmol) of PhI(OAc)$_2$. Pale yellow solid. Yield, 29 mg (30%); mp, 250 °C with decomp. IR (ATR): 1529, 1373 (NO$_2$). $^1$H NMR (400 MHz, DMSO-d$_6$): $\delta$ = 2.78 (3H, s, C-5-CH$_3$); 7.36 (2H, d, H-4′, H-5′, $J$ = 8.8 Hz); 7.40–7.47 (2H, m, H-2′, H-7′); 7.50 (1H, s, H-10′); 7.52–7.58 (2H, m, H-3′, H-6′); 8.21 (2H, d, H-1′, H-8′, $J$ = 8.6 Hz); 8.84 (1H, s, H-2); 14.30 (1H, s, H-3). $^{13}$C $[^1]$H NMR (151 MHz, DMSO-d$_6$): $\delta$ = 21.7; 113.8; 124.9 (2C); 125.1; 125.7 (2C); 127.0 (2C); 128.6; 128.9 (2C); 129.1; 130.6; 134.3; 134.4; 143.9; 150.1; 150.5. Anal. Calcd for C$_{21}$H$_{14}$N$_4$O$_2$: C, 71.18; H, 3.98; N, 15.81. Found: C, 71.26; H, 3.93; N, 15.85.

9-acetoxy-10-oxoanthracene (10). Yellow crystals. Yield, 25 mg (35%). $^1$H NMR (400 MHz, DMSO-d$_6$): $\delta$ = 2.19 (3H, s, CH$_3$); 7.15 (1H, s, CH); 7.56–7.64 (4H, m, H-2′, H-3′, H-6′, H-7′); 7.70–7.76 (2H, m, H-1′, H-8′); 8.15–8.21 (2H, m, H-4′, H-5′). Mass spectrum, $m/z$ (I, %): 208 (100) [M$^+$]; 180 (80), 152 (79), 126 (14), 90 (10), 76 (62), 63 (16), 50 (20), 39 (3).

Anthraquinone (11). Yellow crystals. Yield, 15 mg (25%). $^1$H NMR (400 MHz, DMSO-d$_6$): $\delta$ = 7.88-7.94 (4H, m, H-2′, H-3′, H-6′, H-7′); 8.21–8.26 (4H, m, H-1′, H-4′, H-5′, H-8′). Mass spectrum, $m/z$ (I, %): 252 (13) [M$^+$]; 210 (100); 193 (43); 181 (14); 165 (33); 152 (16); 139 (6); 82 (18); 69 (9); 43 (15).

6-Nitro-5-methyl-7-(thiophen-2′-yl)pyrazolo[1,5-a]pyrimidine (9f). The reaction was performed according to the general procedure 2, employing 0.38 mmol of heterocycle 8f and 0.154 + 0.061 g (0.48 + 0.19 mmol) of PhI(OAc)$_2$. Light orange solid. Yield, 59 mg (60%); mp, 219 °C with decomp. IR (ATR): 1520, 1366 (NO$_2$). $^1$H NMR (400 MHz, DMSO-d$_6$): $\delta$ = 2.59 (3H, s, C-5-CH$_3$); 5.84 (1H, s, H-5); 7.29–7.34 (1H, m, H-3′); 7.48–7.53 (1H, m, H-4′); 7.98–8.02 (1H, d, H-5′); 8.33 (1H, s, H-2); 14.19 (1H, s, H-3). $^{13}$C $[^1]$H NMR (151 MHz, DMSO-d$_6$): $\delta$ = 20.8; 110.8; 128.5; 128.9; 130.0; 131.2; 131.3; 134.3; 140.4; 149.5; 150.2. Anal. Calcd for C$_{11}$H$_8$N$_4$O$_2$: C, 50.76; H, 3.10; N, 21.53. Found: C, 50.73; H, 3.05; N, 21.60.

4. Conclusions

Thus, we can conclude that 6-nitrozolo[1,5-a]pyrimidines, even containing an electron donating substituent at position seven, are capable of oxidation with the formation of an aromatic structure. On the other hand, during oxidation, it is necessary to take into consideration the features of these structures since the reaction is often complicated by a side process. However, there is no reason to suppose that the same compounds cannot be obtained by any alternative synthetic approach that excludes the destructive nature of key intermediates. Nevertheless, the obtained experimental and theoretical data correlate well
with each other, which indicates the possibility of using this set of methods to study the oxidation reactions of this class of organic compounds.

**Supplementary Materials:** Figures with HOMO distribution, Cyclic voltammograms, and NMR Spectra of compounds 4–11.

**Author Contributions:** Synthesis, D.N.L.; quantum-chemical calculation, I.A.B.; electro-chemical experiment, A.V.S.; methodology, E.N.U., O.N.C. and D.N.L.; writing, V.L.R. and D.N.L. All authors have read and agreed to the published version of the manuscript.

**Funding:** The synthetic part was supported by the Ministry of Science and Higher Education of the Russian Federation, State Contract no FEUZ-2020-0058 (H687.42B.223/20). The electrochemical research and the quantum chemical calculations was funded by Russian Foundation for Basic Research (RFBR), project number 20-03-00814.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Data are contained within article.

**Acknowledgments:** DFT computations were performed on the Uran supercomputer at the IMM UB RAS. The team of authors would like to thank the Laboratory for Comprehensive Research and Expert Evaluation of Organic Materials under the direction of O. S. Eltsov.

**Conflicts of Interest:** The authors declare no conflict of interest.

**Sample Availability:** Samples of the compounds 4–11 are available from the authors.

**References**

1. Pinheiro, S.; Pinheiro, E.M.C.; Muri, E.M.F.; Pessôa, J.C.; Cadorini, A.M.; Greco, S.J. Biological Activities of [1,2,4]Triazolo[1,5-a]Pyrimidines and Analogues. *Med. Chem. Res.* 2020, 29, 1751–1776. [CrossRef]

2. Oukoloff, K.; Lucero, B.; Francisco, K.R.; Brunden, K.R.; Ballatore, C. 1,2,4-Triazolo[1,5-a]Pyrimidines in Drug Design. *Eur. J. Med. Chem.* 2019, 165, 332–346. [CrossRef] [PubMed]

3. Fischer, G. Recent Advances in 1,2,4-Triazolo[1,5-a]Pyrimidine Chemistry. In *Advances in Heterocyclic Chemistry*; Academic Press Inc.: Cambridge, MA, USA, 2019; Volume 128, pp. 1–101. [CrossRef]

4. Tigreros, A.; Aranzazu, S.-L.; Bravo, N.-F.; Zapata-Rivera, J.; Portilla, J. Pyrazolo[1,5-a]Pyrimidines-Based Fluorophores: A Comprehensive Theoretical-Experimental Study. *RSC Adv.* 2020, 10, 39542–39552. [CrossRef]

5. Tigreros, A.; Castillo, J.C.; Portilla, J. Cyanide Chemosensors Based on 3-Dicyanovinylpyrazolo[1,5-a]Pyrimidines: Effects of Peripheral 4-Anisyl Group Substitution on the Photophysical Properties. *Talanta* 2020, 215, 120905. [CrossRef]

6. Zhang, M.; Cheng, R.; Lan, J.; Zhang, H.; Yan, L.; Pu, X.; Huang, Z.; Wu, D.; You, J. Oxidative C-H/C-H Cross-Coupling of [1,2,4]Triazolo[1,5-a]Pyrimidines with Indoles and Pyrroles: Discovering Excited-State Intramolecular Proton Transfer (ESIPT) Fluorophores. *Org. Lett.* 2019, 21, 4058–4062. [CrossRef]

7. Tigreros, A.; Rosero, H.A.; Castillo, J.C.; Portilla, J. Integrated Pyrazolo[1,5-a]Pyrimidine–Hemicyanine System as a Colorimetric and Fluorometric Chemosensor for Cyanide Recognition in Water. *Talanta* 2019, 196, 395–401. [CrossRef]

8. Lakomska, I.; Śmiłowicz, D.; Jakubowski, D.; Sitkowski, M.; Wojtczak, A. Materials Platinum(II) Complexes with Bulky Disubstitute Triazolopyrimidines as Promising Materials for Anticancer Agents. *Materials* 2020, 13, 5312. [CrossRef]

9. Esteban-Parra, G.M.; Sebastián, E.S.; Cepeda, J.; Sánchez-González, C.; Rivas-García, L.; Llopis, J.; Aranda, P.; Sánchez-Moreno, M.; Quiro, M.; Rodriguez-Diéguez, A. Anti-Diabetic and Anti-Parasitic Properties of a Family of Luminescent Zinc Coordination Compounds Based on the 7-Amino-5-Methyl-1,2,4-Triazolo[1,5-a]Pyrimidine Ligand. *J. Inorg. Biochem.* 2020, 212, 112325. [CrossRef]

10. Fandzloch, M.; Augustyniak, A.W.; Dobrzańska, L.; Jędrzejewski, T.; Sitkowski, J.; Wypij, M.; Golńska, P. First Dinuclear Rhodium(II) Complexes with Triazolopyrimidines and the Prospect of Their Potential Biological Use. *J. Inorg. Biochem.* 2020, 210, 111072. [CrossRef]

11. Shen, J.; Deng, X.; Sun, R.; Tavallaei, M.S.; Wang, J.; Cai, Q.; Lam, C.; Lei, S.; Fu, L.; Jiang, F. Structural Optimization of Pyrazolo[1,5-a]Pyrimidine Derivatives as Potent and Highly Selective DPP-4 Inhibitors. *Eur. J. Med. Chem.* 2020, 208, 112850. [CrossRef] [PubMed]

12. Peytam, F.; Adib, M.; Shourgeshty, R.; Firoozpour, L.; Rahmanian-Jazi, M.; Jahani, M.; Moghim, S.; Divsalar, K.; Faramarzi, M.A.; Mojtabavi, S.; et al. An Efficient and Targeted Synthetic Approach towards New Highly Substituted 6-Amino-Pyrazolo[1,5-a]Pyrimidines with α-Glucosidase Inhibitory Activity. *Sci. Rep.* 2020, 10, 2595. [CrossRef] [PubMed]
13. Kato, N.; Oka, M.; Murase, T.; Yoshida, M.; Sakairi, M.; Yamashita, S.; Yasuda, Y.; Yoshikawa, A.; Hayashi, Y.; Makino, M.; et al. Discovery and Pharmacological Characterization of N-[2-[2-[(2S)-2-Cyanopyrrolidin-1-Yl]-2-Oxoethyl][amino]-2-Methylpyrazolo[1,5-a]Pyrimidine-6-Carboxamide Hydrochloride (Anaglipin Hydrochloride Salt) as a Potent and Selective DPP-IV Inhibitor. *Bioorg. Med. Chem.* 2011, 19, 7221–7227. [CrossRef] [PubMed]

14. Wan, Y.H.; Wu, W.Y.; Guo, S.X.; He, S.J.; Tang, X.D.; Wu, X.Y.; Nandakumar, K.S.; Zou, M.; Li, L.; Chen, X.G.; et al. [1,2,4]Triazolo[1,5-a]Pyrimidine Derivative (Mot-5) Is a New NS5-RdRp Inhibitor of DENV2 Proliferation and DENV2-Induced Inflammation. *Acta Pharm. Sin.* 2020, 41, 706–718. [CrossRef] [PubMed]

15. Yamaguchi-Sasaki, T.; Tamura, Y.; Ogata, Y.; Kawaguchi, T.; Kurosaka, J.; Sugaya, Y.; Iwakiri, K.; Busujima, T.; Takahashi, R.; Ueda-Yonemoto, N.; et al. Design and Synthesis of 2-(1-Alkylaminoalkyl)Pyrazolo[1,5-a]Pyrimidines as New Respiratory Syncytial Virus Fusion Protein Inhibitors. *Chem. Pharm. Bull.* 2020, 68, 345–362. [CrossRef] [PubMed]

16. Massari, S.; Nannetti, G.; Desantis, J.; Muratore, G.; Sabatini, S.; Manfroni, B.; Mercorelli, B.; Cecchetti, V.; Palu, G.; Cruciani, G.; et al. A Broad Anti-Influenza Hybrid Small Molecule That Potently Disrupts the Interaction of Polymerase Acidic Protein–Base Protein 1 (PA-PB1) Subunits. *J. Med. Chem.* 2015, 58, 3830–3842. [CrossRef]

17. Wang, H.; Lee, M.; Peng, Z.; Blázquez, B.; Lastochkin, E.; Kumaran, M.; Bouley, R.; Chang, M.; Mobashery, S. Synthesis and Evaluation of 1,2,4-Triazolo[1,5-a]Pyrimidines as Antibacterial Agents against Enterococcus Faecium. *J. Med. Chem.* 2015, 58, 4194–4203. [CrossRef]

18. Zuniga, E.S.; Korkegian, A.; Mullen, S.; Hembre, E.J.; Ornstein, P.L.; Cortez, G.; Biswas, K.; Kumar, N.; Cramer, J.; Masquelin, T.; et al. The Synthesis and Evaluation of Triazolopyrimidines as Anti-Tubercular Agents. *Bioorg. Med. Chem.* 2017, 25, 3922–3946. [CrossRef]

19. Ding, J.; Cao, F.D.; Geng, Y.R.; Tian, Y.; Li, P.; Li, X.F.; Huang, L.J. Synthesis and in Vitro Anti-Epileptic Activities of Novel[1,2,4]-Triazolo[1,5-a]Pyrimidin-7(4H)-One Derivatives. *J. Asian Nat. Prod. Res.* 2019, 21, 1190–1204. [CrossRef]

20. Sullivan, S.K.; Petroski, R.E.; Verge, G.; Gross, R.S.; Foster, A.C.; Grigoriadis, D.E. Characterization of the Interaction of Indiplon, a Novel Pyrazolopyrimidine Sedative-Hypnotic, with the GABA\(_A\) Receptor. *J. Pharmacol. Exp. Ther.* 2004, 311, 537–546. [CrossRef]

21. Huo, J.L.; Wang, S.; Yuan, X.H.; Yu, B.; Zhao, W.; Liu, H.M. Discovery of [1,2,4]Triazolo[1,5-a]Pyrimidines Derivatives as Potential Anticancer Agents. *Eur. J. Med. Chem.* 2015, 111, 13108. [CrossRef]

22. Krämer, A.; Kurz, C.G.; Berger, B.T.; Celik, I.E.; Tjaden, A.; Hanke, T. Optimization of Pyrazolo[1,5-a]Pyrimidines Lead to the Identification of a Highly Selective Casein Kinase 2 Inhibitor. *Eur. J. Med. Chem.* 2020, 208, 112770. [CrossRef] [PubMed]

23. Wang, S.; Wang, S.-Q.; Teng, Q.-X.; Yang, L.; Lei, Z.-N.; Yuan, X.-H.; Huo, J.-F.; Wang, M.; Yu, B.; et al. Structure-Based Design, Synthesis, and Biological Evaluation of New Triazolo[1,5-a]Pyrimidine Derivatives as Highly Potent and Orally Active ABCB1 Modulators. *J. Med. Chem.* 2020, 63, 15979–15996. [CrossRef]

24. Li, G.; Wang, Y.; Li, L.; Ren, Y.; Deng, X.; Liu, J.; Wang, W.; Luo, M.; Liu, S.; Chen, J. Design, Synthesis, and Bioevaluation of Pyrazolo[1,5-a]Pyrimidine Derivatives as Tubulin Polymerization Inhibitors Targeting the Colchicine Binding Site with Potent Anticancer Activities. *Eur. J. Med. Chem.* 2020, 202. [CrossRef]

25. Mathison, C.; Chianelli, D.; Rucker, P.; Nelson, J.; Roland, J.; Huang, Z.; Yang, Y.; Jiang, J.; Feng Xie, Y.; Epplle, R.; et al. Efficacy and Tolerability of Pyrazolo[1,5-a]Pyrimidine RET Kinase Inhibitors for the Treatment of Lung Adenocarcinoma. *ACS Med. Chem. Lett.* 2020, 11, 558–565. [CrossRef]

26. Badolato, M.; Manetti, F.; Garofalo, A.; Aiello, F. Triazolopyrimidinium Salts: Discovery of a New Class of Agents for Cancer Therapy. *Future Med. Chem.* 2020, 12, 387–402. [CrossRef]

27. Oukoloff, K.; Nzou, G.; Varricchio, C.; Lucero, B.; Alle, T.; Kovalevich, J.; Monti, L.; Cornec, A.-S.; Yao, Y.; James, M.; et al. Evaluation of the Structure–Activity Relationship of Microtubule-Tubulin-Targeting 1,2,4-Triazolo[1,5-a]Pyrimidines Identifies New Candidates for Neurodegenerative-Hypersensitivity. *J. Med. Chem.* 2021, 64, 1073–1102. [CrossRef]

28. Uryu, S.; Tokuhiro, S.; Murasugi, T.; Oda, T. A Novel Compound, RS-1178, Specifically Inhibits Neuronal Cell Death Mediated by \(\beta\)-Amyloid-Induced Macrophage Activation in Vitro. *Brain Res.* 2002, 946, 298–306. [CrossRef]

29. Lou, K.; Yao, Y.; Hoye, A.T.; James, M.J.; Cornec, A.-S.; Hyde, E.; Gay, B.; Lee, V.; Trojanowski, J.Q.; Smith, A.B.; et al. Brain-Penetrant, Orally Bioavailable Microtubule-Stabilizing Small Molecules Are Potential Candidate Therapeutics for Alzheimer’s Disease and Related Tauopathies. *J. Med. Chem.* 2014, 57, 6116–6127. [CrossRef] [PubMed]

30. Rusinov, V.L.; Charushin, V.N.; Chupakhin, O.N. Biologically Active Azolo-1,2,4-Triazines and Azolopyrimidines. *Russ. Chem.Bull.* 2015, 64, 1378–1384. [CrossRef]
